Abstract: P716

Title: IMPROVEMENT OF TREATMENT-FREE REMISSION RATE FOLLOWING DISCONTINUATION OF BCR::ABL1 TKI WITH A FASTER INITIAL DECLINE OF BCR::ABL1 TRANSCRIPT AND LONGER TREATMENT DURATION IN CHRONIC MYELOID LEUKEMIA

Abstract Type: Poster Presentation

Topic: Chronic myeloid leukemia - Clinical

Background:

Over recent years, numerous clinical studies have demonstrated that approximately one-half of patients with chronic phase chronic myeloid leukemia (CP-CML) who receive sufficient tyrosine kinase inhibitors (TKIs) and achieve and maintain a deep molecular response (DMR) are able to successfully discontinue therapy. In this context, Treatment free remission (TFR) is a major goal for all CML patients according to the current guidelines and the main factors affecting TFR are the duration of TKIs treatment and the duration of DMR maintenance during TKI treatment.

Aims:

This study analyzed the TFR success rate in CP-CML patients who maintained DMR for 4 years or more and investigated whether new clinical application criteria could be derived with TFR study of longer TKI treatment duration and DMR duration.

Methods:

Among patients newly diagnosed with CP-CML and treated at least one of TKIs (Imatinib, Nilotinib, Dasatinib, Bosutinib, and Radotinib) as the first treatment, patients who maintained MR4.5 (*BCR::ABL1* IS ≤0.0032%) continuously for at least 4 years through reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) tests were enrolled in this study. After discontinuation, molecular responses were monitored using the RT-qPCR method. In the case of relapse, defined as loss of major molecular response (MMR), the last TKI therapy with same dose was reintroduced, and molecular responses after resumption were monitored monthly until achievement of MMR using RT-qPCR.

Results:

Altogether 116 patients (50 males and 66 females) discontinued TKI. Median age at diagnosis was 43.0 years (range, 40.8-45.3) and the percentages of patients with low, intermediate and high Sokal risk scores ware 58 (50.0%), 35 (30.2%) and 18 (15.5%) patients, respectively with unknown Sokal risk scores in 5 (4.3%) patients. The percentage of patients with low and high EUTOS scores was 69.8% and 6.0%, respectively and 24.1% had an unknown risk. Prior to discontinuation, all patients received TKIs for a median of 118.0 months (range, 63.6-224.7), and the duration of sustained MR4.5 was 67.4 months (range, 48.6-157.9). At the time of discontinuation, 93 patients (80.2%) were using first-line TKI. The patient-specific calculated halving time of BCR::ABL1 after starting TKI treatment to determine early molecular kinetics was median 11.1 days (range, 3.3-722.2).

After a median follow-up from treatment discontinuation of 28.0 months (range, 10.9-150.7), the TFR rates at 12, 24, and 48 months were 81.9%, 76.0%, and 71.0%, respectively (Figure 1). 88 patients were still free of treatment with sustained MR4.5. Despite 45 patients losing UMRD, 17 patients were able to regain their MMR, while 28 (24.1%) patients have lost MMR at a median of 8.4 months (range, 1.8-42.0) after discontinuation; 18 (64.3%) patients had molecular relapse within 6 months of TKI discontinuation. No progression toward advanced-phase CML occurred, and when 28 patients who lost MMR were retreated with same TKI, 26 patients (92.9%) re-achieved MMR with a median of 5.6 months (range, 2.3-23.4). Variables demonstrating a significant association on univariate analysis were EUTOS risk score, total duration of TKI therapy and halving time.

Summary/Conclusion:

Our result demonstrates that TFR rate can be improved in patients who received TKI treatment for approximately 10 years and maintained DMR for more than 6 years regardless of the type of TKI. Based on results, we can confirm that a more rapid initial *BCR::ABL1* decline after commencing TKI and total duration of TKI therapy correlated with an increased probability of achieving TFR eligibility.

Characteristic All Patients (N=116) Age, median (range) Sex, N (%) Male Female 50 (43.1) Female 66 (56.9) Sokal score, N (%) Low 58 (50.0) Intermediate High 18 (15.5) N/A 5 (4.3) EUTOS, N (%) Low 81 (69.8) High 7 (6.0) N/A 28 (24.1) Halving time Value available, N (%) Median halving time, day Duration of TKI treatment, month Time from TKI start to cessation, median (range) Time from 1ª. MR4.0 to TKI cessation, median (range) Time from 1ª. MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) 10ss of MMRD, N (%) Loss of MMRD, N (%) 10ss of MMRD, N (%) 10ss of MMR, N (%) 10ss of MMR, N (%) 10ss of MMR, N (%) 110 (33.8) 111 (33.722.2) 111 (33.722.3) 112 (33.8) 113 (39.932.3) 114 (39.932.3) 115 (39.932.3) 116 (39.932.3) 117 (48.6-157.9) 118 (19.932.3) 119 (19.9150.7) 119 (19.932.3) 110 (19.9150.7) 110 (19.932.3) 111 (19.933.3) 111 (19.933.4) 111 (19.933.				
Sex, N (%) Male 50 (43.1) Female 66 (56.9) Sokal score, N (%)	Characteristic		All Patients (N=116)	
Male 50 (43.1) Female 66 (56.9) Sokal score, N (%) Low 58 (50.0) Intermediate 35 (30.2) High 18 (15.5) N/A 5 (4.3) EUTOS, N (%) Low 81 (69.8) High 7 (6.0) N/A 28 (24.1) Halving time Value available, N (%) 64 (55.2%) Median halving time, day 11.1 (3.3-722.2) Duration of TKI treatment, month Time from TKI start to cessation, median (range) 118.0 (63.6-224.7) Time from 1 st . MR4.0 to TKI cessation, median (range) 77.8 (48.6-157.9) Time from 1 st . MR4.5 to TKI cessation, median (range) 67.4 (48.6-157.9) Follow-up duration (months), median (range) 28.0 (10.9-150.7) Loss of UMRD, N (%) 28 (24.1) CMR re-achievement, N (%) 26 (92.9%, 26/28) Time to CMR re-achievement, N (%) 7.84 (1.3-2.3-2.4) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Age, median (range)		43.0 (40.8-45.3)	
Sokal score, N (%)	Sex, N (%)			
Sokal score, N (%) S8 (50.0) Low 58 (50.0) Intermediate 35 (30.2) High 18 (15.5) N/A 5 (4.3) EUTOS, N (%) 81 (69.8) High 7 (6.0) N/A 28 (24.1) Halving time Value available, N (%) Median halving time, day 11.1 (3.3-722.2) Duration of TKI treatment, month Time from TKI start to cessation, median (range) Time from 1 st . MR4.0 to TKI cessation, median (range) 77.8 (48.6-157.9) Time from 1 st . MR4.5 to TKI cessation, median (range) 67.4 (48.6-157.9) Follow-up duration (months), median (range) 28.0 (10.9-150.7) Loss of UMRD, N (%) 28 (24.1) Loss of MMR, N (%) 28 (24.1) CMR re-achievement, N (%) 26 (92.9%, 26/28) Time to CMR re-achievement, months (range) 5.6 (2.3-23.4) Univariable Analysis HR 95% CI EUTOS risk score 1.00 1.149-15.225 .030 Low 5.184 1.913-14.044 .001 High 4.183 1.149-15.225 .030 211.1 4.183 <td colspan="2">Male</td> <td colspan="2">50 (43.1)</td>	Male		50 (43.1)	
Low	Female		66 (56.9)	
Intermediate	Sokal score, N (%)			
High 18 (15.5) N/A 5 (4.3) EUTOS, N (%) Low 81 (69.8) High 7 (6.0) N/A 28 (24.1) Halving time Value available, N (%) 64 (55.2%) Median halving time, day 11.1 (3.3-722.2) Duration of TKI treatment, month Time from TKI start to cessation, median (range) 77.8 (48.6-157.9) Time from 1". MR4.0 to TKI cessation, median (range) 77.8 (48.6-157.9) Time from 1". MR4.5 to TKI cessation, median (range) 67.4 (48.6-157.9) Follow-up duration (months), median (range) 28.0 (10.9-150.7) Loss of UMRD, N (%) 45 (38.8) Loss of MMR, N (%) 28 (24.1) CMR re-achievement, N (%) 26 (92.9%, 26/28) Time to CMR re-achievement, months (range) 5.6 (2.3-23.4) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Low		58 (50.0)	
N/A 5 (4.3) EUTOS, N (%) Low 81 (69.8) High 7 (6.0) N/A 28 (24.1) Halving time Value available, N (%) 64 (55.2%) Median halving time, day 11.1 (3.3-722.2) Duration of TKI treatment, month Time from TKI start to cessation, median (range) 77.8 (48.6-157.9) Time from 1° .MR4.0 to TKI cessation, median (range) 77.8 (48.6-157.9) Time from 1° .MR4.5 to TKI cessation, median (range) 67.4 (48.6-157.9) Follow-up duration (months), median (range) 28.0 (10.9-150.7) Loss of UMRD, N (%) 45 (38.8) Loss of MMR, N (%) 28 (24.1) CMR re-achievement, N (%) 26 (92.9%, 26/28) Time to CMR re-achievement, months (range) 5.6 (2.3-23.4) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Intermediate		35 (30.2)	
EUTOS, N (%) Low	High		18 (15.5)	
Low High N/A 181 (69.8) High N/A 28 (24.1) Halving time Value available, N (%) Median halving time, day Duration of TKI treatment, month Time from TKI start to cessation, median (range) Time from 1st. MR4.0 to TKI cessation, median (range) Time from 1st. MR4.0 to TKI cessation, median (range) Time from 1st. MR4.5 to TKI cessation, median (range) Time from 1st. MR4.			5 (4.3)	
High 7 (6.0) N/A 28 (24.1) Halving time Value available, N (%) 64 (55.2%) Median halving time, day 11.1 (3.3-722.2) Duration of TKI treatment, month Time from TKI start to cessation, median (range) 118.0 (63.6-224.7) Time from 1 st . MR4.0 to TKI cessation, median (range) 77.8 (48.6-157.9) Time from 1 st . MR4.5 to TKI cessation, median (range) 67.4 (48.6-157.9) Follow-up duration (months), median (range) 28.0 (10.9-150.7) Loss of UMRD, N (%) 45 (38.8) Loss of MMR, N (%) 28 (24.1) CMR re-achievement, N (%) 26 (92.9%, 26/28) Time to CMR re-achievement, months (range) 5.6 (2.3-23.4) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	EUTOS, N (%)			
N/A Halving time Value available, N (%) Median halving time, day Duration of TKI treatment, month Time from TKI start to cessation, median (range) Time from 1st. MR4.0 to TKI cessation, median (range) Time from 1st. MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) Follow-up duration (months), median (range) Loss of UMRD, N (%) Loss of MMR, N (%) CMR re-achievement, N (%) Time to CMR re-achievement, months (range) Low Solution John 1st. MR4.5 to TKI cessation, median (range) EUTOS risk score Low Solution John 1st. MR4.5 to TKI cessation, median (range) Solution John 1st. MR4.5 to TKI cessation, median (range) EUTOS risk score Low Solution John 1st. MR4.5 to TKI cessation, median (range) Solution John 1st. MR4.5 to TKI cessation, median (range) EUTOS risk score Low Solution John 1st. MR4.5 to TKI cessation, median (range) Solution John 1st. MR4.5 to TKI cessation, median (range) Solution John 1st. MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) Boh 1st. MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) Boh 1st. MR4.5 to TKI cessation, median (range) Follow-up duration (months),	Low		81 (69.8)	
Halving time Value available, N (%) Median halving time, day Duration of TKI treatment, month Time from TKI start to cessation, median (range) Time from 1st. MR4.0 to TKI cessation, median (range) Time from 1st. MR4.5 to TKI cessation, median (range) Time from 1st. MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) EVALUATE STATE	High			
Value available, N (%) Median halving time, day Duration of TKI treatment, month Time from TKI start to cessation, median (range) Time from 1st. MR4.0 to TKI cessation, median (range) Time from 1st. MR4.5 to TKI cessation, median (range) Time from 1st. MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) Loss of UMRD, N (%) Loss of UMRD, N (%) Loss of MMR, N (%) CMR re-achievement, N (%) Univariable Analysis HR Solution Univariable Analysis HR Solution FEUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 211.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	N/A		28 (24.1)	
Median halving time, day	Halving time			
Duration of TKI treatment, month Time from TKI start to cessation, median (range) 118.0 (63.6-224.7) Time from TKI start to cessation, median (range) 77.8 (48.6-157.9) Time from 1st. MR4.5 to TKI cessation, median (range) 67.4 (48.6-157.9) Follow-up duration (months), median (range) 28.0 (10.9-150.7) Loss of UMRD, N (%) 45 (38.8) Loss of MMR, N (%) 28 (24.1) CMR re-achievement, N (%) 26 (92.9%, 26/28) Time to CMR re-achievement, months (range) 5.6 (2.3-23.4) Univariable Analysis HR 95% CI FUTOS risk score P Low 5.184 1.913-14.044 .001 High Halving time, days <11.1	Value available, N (%)		64 (55.2%)	
Time from TKI start to cessation, median (range) Time from 1 st . MR4.0 to TKI cessation, median (range) Time from 1 st . MR4.5 to TKI cessation, median (range) Time from 1 st . MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) Loss of UMRD, N (%) Loss of MMR, N (%) CMR re-achievement, N (%) Time to CMR re-achievement, months (range) Univariable Analysis HR 95% CI FUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Median halving time, day		11.1 (3.3-722.2)	
Time from 1 st . MR4.0 to TKI cessation, median (range) Time from 1 st . MR4.5 to TKI cessation, median (range) Follow-up duration (months), median (range) Loss of UMRD, N (%) Loss of MMR, N (%) Loss of	Duration of TKI treatment, mo	onth		
Time from 1st MR4.5 to TKI cessation, median (range) 67.4 (48.6-157.9) Follow-up duration (months), median (range) 28.0 (10.9-150.7) Loss of UMRD, N (%) 45 (38.8) Loss of MMR, N (%) 28 (24.1) CMR re-achievement, N (%) 26 (92.9%, 26/28) Time to CMR re-achievement, months (range) 5.6 (2.3-23.4) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Time from TKI start to cessation, median (range)		118.0 (63.6-224.7)	
Follow-up duration (months), median (range) Loss of UMRD, N (%) Loss of MMR, N (%) Loss of MMR, N (%) CMR re-achievement, N (%) Univariable Analysis HR 95% CI F EUTOS risk score Low 5.184 Halving time, days <11.1 4.183 1.149-15.225 .030 28.0 (10.9-150.7) 45 (38.8) 28 (24.1) 26 (92.9%, 26/28) F EUTOS risk score 1.1913-14.044 .001 High Halving time, days <11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Time from 1st. MR4.0 to TKI cessation, median (range)		77.8 (48.6-157.9)	
Loss of UMRD, N (%) Loss of MMR, N (%) Loss of MMR, N (%) CMR re-achievement, N (%) Time to CMR re-achievement, months (range) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 H.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 211.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Time from 1st. MR4.5 to TKI cessation, median (range)		67.4 (48.6-157.9)	
Loss of MMR, N (%) CMR re-achievement, N (%) Time to CMR re-achievement, months (range) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 High Halving time, days <11.1 ≥11.1 TKI duration, months <118.0 0.384 28 (24.1) 29 (24.1) 20 (92.9%, 26/28) 5.6 (2.3-23.4) P EUTOS risk score 1.913-14.044 .001 1.913-14.044 .001 1.149-15.225 .030 2.11.1 TKI duration, months	Follow-up duration (months), median (range)		28.0 (10.9-150.7)	
CMR re-achievement, N (%) Time to CMR re-achievement, months (range) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 211.1 211.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Loss of UMRD, N (%)		45 (38.8)	
Time to CMR re-achievement, months (range) 5.6 (2.3-23.4) Univariable Analysis HR 95% CI P EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Loss of MMR, N (%)		28 (24.1)	
Univariable Analysis HR 95% CI P EUTOS risk score 1.913-14.044 .001 Low 5.184 1.913-14.044 .001 High 4.183 1.149-15.225 .030 ≥11.1 2.11.1 1.149-15.225 .030 TKI duration, months 0.169-0.873 .022	CMR re-achievement, N (%)		26 (92.9%, 26/28)	
EUTOS risk score Low 5.184 1.913-14.044 .001 High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Time to CMR re-achievement,	months (range)		
Low 5.184 1.913-14.044 .001 High .001 Halving time, days .01.1 .030 ≥11.1 .030 .030 TKI duration, months .0169-0.873 .022	Univariable Analysis	HR	95% CI	P
High Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	EUTOS risk score			
Halving time, days <11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Low	5.184	1.913-14.044	.001
<11.1 4.183 1.149-15.225 .030 ≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	High			
≥11.1 TKI duration, months <118.0 0.384 0.169-0.873 .022	Halving time, days			
TKI duration, months <118.0 0.384 0.169-0.873 .022	<11.1	4.183	1.149-15.225	.030
<118.0 0.384 0.169-0.873 .022				
	TKI duration, months			
×110.0		0.384	0.169-0.873	.022
<110.U	≥118.0			




Figure 1. Treatment-free remission rates overall

Keywords: treatment-free remission, Chronic myeloid leukemia, Tyrosine kinase inhibitor, BCR::ABL